The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive
Publications
Granulomatosis with polyangiitis following Pfizer-BioNTech COVID-19 vaccination.
Modern rheumatology case reports. 2023;7(1):127-129
Case Report: ANCA-Associated Vasculitis Presenting With Rhabdomyolysis and Pauci-Immune Crescentic Glomerulonephritis After Pfizer-BioNTech COVID-19 mRNA Vaccination.
Frontiers in immunology. 2021;12:762006
Antineutrophil Cytoplasmic Autoantibody-Associated Glomerulonephritis Following the Pfizer-BioNTech COVID-19 Vaccine.
Kidney international reports. 2021;6(12):3087-3089
Villa M, Díaz-Crespo F, Pérez de José A, Verdalles Ú, Verde E, Almeida Ruiz F, Acosta A, Mijaylova A, Goicoechea M
A case of ANCA-associated vasculitis after AZD1222 (Oxford-AstraZeneca) SARS-CoV-2 vaccination: casualty or causality?
Kidney international. 2021;100(4):937-938
ANCA-Associated Vasculitis Following Pfizer-BioNTech COVID-19 Vaccine.
American journal of kidney diseases : the official journal of the National Kidney Foundation. 2021;78(4):611-613